Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, Baylor Collaborate on Customized CGH Microarrays

NEW YORK (GenomeWeb News) – Agilent Technologies today said that it is collaborating with Baylor College of Medicine's Medical Genetics Laboratories to provide customized comparative genomics hybridization microarrays to researchers.

Baylor has designed six new microarrays that combined with Agilent's microarray manufacturing capabilities will "enable advanced discoveries in cancer and cytogenetics research," Agilent said.

"Originally focused on microdeletions and microduplications, our current designs have been continually improved over the past 10 years and are now highly robust, with the ability to detect exon-level deletions and duplications," Brandon Perthuis, director of business development at the BCM Medical Genetic Laboratories, said in a statement. "Our exon array targets approximately 1,700 genes and includes probes used for SNP analysis for the detection" of absence of heterozygosity and uniparental disomy.

Financial and other terms of the deal were not disclosed.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.